INTRODUCTION: This study was performed to compare the efficacy and safety of PreserFlo MicroShunt (PMS) implantation with mitomycin C (MMC) applied by sub-tenon injection versus conventional application by MMC-soaked sponges. METHODS: This retrospective, 1-year cohort study included 100 eyes of 100 patients with glaucoma who underwent PMS implantation with MMC (0.4 mg/ml) delivered either by sub-tenon injection (50 eyes) or via soaked sponges (50 eyes). The primary outcome measure at 1 year was intraocular pressure (IOP) reduction, with complete success defined as an IOP reduction of ≥ 20% and achieving a target IOP of ≤ 21 or 18 mmHg without the use of medication. Secondary outcomes, including corneal endothelial cell density (CECD) loss, the number of medications, and complications, were assessed and compared between the groups. RESULTS: Sustained reductions in mean IOP were observed in both groups over the 1-year follow-up, with no significant differences between the groups. The complete success rate, with a target IOP of ≤ 21 mmHg after 1 year, was 19.3% in the sponge group and 26.4% in the injection group. The qualified success rate was 59.0% and 87.4% in the sponge and injection groups, respectively. A longer survival rate was observed in the injection group than in the sponge group when IOP was below 21 mmHg. The mean CECD significantly decreased (P < 0.01) from baseline to each postoperative follow-up time point in both groups. At 1 year postoperatively, the percentage of total CECD loss was 8.1% in the sponge group and 8.0% in the injection group. However, no significant differences in mean CECD values, the number of medications, or adverse events were found between the groups. CONCLUSIONS: PMS implantation with sub-tenon injection of MMC was comparable in terms of efficacy and safety to traditional MMC delivery via soaked sponges. However, the injection group demonstrated a significantly higher success rate than the sponge group.
- Publikační typ
- časopisecké články MeSH
BACKGROUND AND AIMS: Currently around 67 million people in Europe are affected by some form of age-related macular degeneration (AMD). As most known types of vitreoretinal (VR) interface disorders can coexist with AMD and as we can favourably affect the former with vitreoretinal surgery, our goal was to evaluate the results of vitreoretinal interface disorder surgery with macular peeling in relation to coincident intermediate stage AMD. METHODOLOGY: This was a retrospective evaluation of eyes operated with 25-gauge pars plana vitrectomy (PPV). The monitored parameters were anatomical and functional findings and, safety of the procedure. The surface of the macula was stained with trypan blue and treated (peeling) with a disposable microforceps. 10% perfluoropropane, or the air tamponade was used. Distance visual acuity was examined on the ETDRS chart, the macular finding was monitored by OCT and photodocumented. The post-operative face-down position was 3-5 days. The follow-up period was 6 months. RESULTS: 17 eyes (14 patients, woman 86%) mean age 74 years. The primary indications for the procedure were: idiopathic macular hole (IMD) 59%, epiretinal membrane 29% and vitreomacular traction syndrome 12%. Ophthalmoscopic and OCT findings of intermediate dry form of AMD (100%), in 24% was drusoid ablation of the pigment leaf. In all cases of IMD, primary closure occurred. Input visual acuity 0.1-0.6 improved to 0.2-0.9 at the end of the follow-up period (P<0.05). No complications during surgery or progression of AMD in the follow-up period were observed. CONCLUSION: PPV for vitreoretinal interface disorders have similar anatomical results, whether the outer part of the retina is disrupted by intermediate AMD or not. Functional results are affected by possible disruption of the RPE or the outer layers of the neuroretina by AMD. The PPV procedure has a standard security profile. It is safe and does not affect the progression of AMD in the short term.
- MeSH
- epiretinální membrána * chirurgie MeSH
- lidé MeSH
- makulární degenerace * komplikace chirurgie MeSH
- nemoci retiny * MeSH
- oční nemoci * chirurgie MeSH
- optická koherentní tomografie MeSH
- perforace sítnice * chirurgie MeSH
- retrospektivní studie MeSH
- senioři MeSH
- vitrektomie metody MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- MeSH
- angiografie klasifikace metody MeSH
- diagnostické techniky oftalmologické * klasifikace MeSH
- fluorescence MeSH
- indokyanová zeleň terapeutické užití MeSH
- lidé MeSH
- makulární degenerace * diagnóza etiologie MeSH
- neovaskularizace choroidey diagnostické zobrazování MeSH
- optická koherentní tomografie dějiny metody MeSH
- optické zobrazování MeSH
- retina diagnostické zobrazování patologie MeSH
- umělá inteligence MeSH
- zraková ostrost fyziologie MeSH
- zraková percepce MeSH
- zrakové testy dějiny klasifikace metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
- MeSH
- biosimilární léčivé přípravky klasifikace terapeutické užití MeSH
- humanizované monoklonální protilátky aplikace a dávkování klasifikace škodlivé účinky MeSH
- injekce intravitreální ošetřování MeSH
- klinická studie jako téma MeSH
- laserová terapie s nízkou intenzitou světla MeSH
- lidé MeSH
- makulární degenerace * farmakoterapie terapie MeSH
- neovaskularizace choroidey diagnóza patologie MeSH
- nežádoucí účinky léčiv epidemiologie klasifikace MeSH
- ranibizumab aplikace a dávkování MeSH
- vaskulární endoteliální růstové faktory antagonisté a inhibitory fyziologie klasifikace MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
- MeSH
- geografická atrofie epidemiologie etiologie MeSH
- injekce intravitreální škodlivé účinky MeSH
- klinická studie jako téma MeSH
- lidé MeSH
- makulární degenerace * farmakoterapie MeSH
- neovaskularizace choroidey etiologie patologie MeSH
- nežádoucí účinky léčiv MeSH
- nitrooční tlak účinky léků MeSH
- rizikové faktory MeSH
- vaskulární endoteliální růstové faktory antagonisté a inhibitory MeSH
- Check Tag
- lidé MeSH
- MeSH
- buněčná smrt fyziologie MeSH
- lidé MeSH
- neuroprotekce * fyziologie MeSH
- retina * fyziologie patofyziologie MeSH
- Check Tag
- lidé MeSH
